| 龚春琳,梁兆光,许文婷,汪 硕,栾天竹.匹伐他汀钙与阿托伐他汀钙治疗冠心病的临床疗效及安全性比较[J].现代生物医学进展英文版,2019,19(17):3293-3296. |
| 匹伐他汀钙与阿托伐他汀钙治疗冠心病的临床疗效及安全性比较 |
| Comparison of the Efficacy and Safety of Pitavastatin Calcium and Atorvastatin Calcium in the Treatmentof Coronary Heart Disease |
| Received:June 18, 2019 Revised:July 13, 2019 |
| DOI：10.13241/j.cnki.pmb.2019.17.019 |
| 中文关键词: 匹伐他汀钙 阿托伐他汀钙 冠心病 |
| 英文关键词: Pitavastatin calcium Atorvastatin calcium Coronary heart disease |
| 基金项目:黑龙江省青年科学基金项目(QC2013C100) |
| Author Name | Affiliation | E-mail | | GONG Chun-lin | Department of seventh Cardiology, The First Hospital Affiliated of Harbin Medical University, Harbin, Heilongjiang, 150001, China | dalin213@126.com | | LIANG Zhao-guang | Department of seventh Cardiology, The First Hospital Affiliated of Harbin Medical University, Harbin, Heilongjiang, 150001, China | | | XU Wen-ting | Department of seventh Cardiology, The First Hospital Affiliated of Harbin Medical University, Harbin, Heilongjiang, 150001, China | | | WANG Shuo | Department of seventh Cardiology, The First Hospital Affiliated of Harbin Medical University, Harbin, Heilongjiang, 150001, China | | | LUAN Tian-zhu | Department of seventh Cardiology, The First Hospital Affiliated of Harbin Medical University, Harbin, Heilongjiang, 150001, China | |
|
| Hits: 903 |
| Download times: 668 |
| 中文摘要: |
| 摘要 目的：观察和比较匹伐他汀钙与阿托伐他汀钙治疗冠心病的临床疗效及安全性。方法：选取2016年3月到2018年12月于我院就诊的冠心病患者共100例，将其按照入院编号随机分为两组，匹伐他汀钙组(50例)与阿托伐他汀钙组(50例)。在服药前及服药后第6、12个月，检测和比较两组血糖(Glu)、糖化血红蛋白(HbA1c)、超敏C反应蛋白(hsCRP)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、谷丙转苷酶(ALT)、谷草转氨酶(AST)、肌酐(Cr)、肌酸激酶(CK)水平的变化。结果：治疗后6、12个月，匹伐他汀钙组血清HDL-C水平较治疗前显著升高(P<0.05)，而血清hsCRP水平明显降低(P<0.05)，阿托伐他汀钙组HDL-C、hsCRP与治疗前比较差异均没有统计学意义(P>0.05)。治疗后12个月，阿托伐他汀钙组HbA1c较治疗前显著升高(P<0.05)，而匹伐他汀钙组与治疗前比较差异没有统计学意义(P>0.05)。治疗后6、12个月，两组患者血清TC、LDL-C水平均较治疗前明显降低(P<0.05)，两组患者血清TG、Glu、ALT、AST、Cr、CK水平较治疗前差异无明显统计学意义(P>0.05)。结论：匹伐他汀钙和阿托伐他汀钙治疗均能够降低冠心病患者的血清LDL-C、TC、TG水平，而匹伐他汀钙同时可升高HDL-C，降低血清hsCRP水平，并且不增加新发糖尿病的风险。 |
| 英文摘要: |
| ABSTRACT Objective: To comparison the efficacy and safety of pivastatin calcium and atorvastatin calcium in the Treatment of Coronary Heart Disease. Methods: 100 patients with coronary heart disease from March 2016 to December 2018 were divided into the pitavastatin calcium group(n=50) and the atorvastatin calcium group (n=50). The blood glucose(Glu), Glycated hemoglobin(HbA1c), Ultra-sensitive C reaction protein(hsCRP), Total cholesterol(TC), Triglycerides(TG), Low density lipoprotein cholesterol(LDL-C),High-density lipoprotein cholesterol(HDL-C), Acetyltransferase(ALT), Valley grass transaminase(AST), Creatinine(Cr), Creatine kinase(CK)were monitored and compared before treatment and after treatment of 6,12 months. Results: After 6months and 12months treatment the pitavastatin calcium group HDL-C were significantly elevated (P<0.05), hsCRP were significantly lower(P<0.05). After 6months and 12months the atorvastatin calcium group HDL-C and hsCRP compared to before treatment the difference were not statistically(P>0.05).The atorvastatin calcium group HbA1c were elevated after 12months treatment with statistically differences(P<0.05), but the pitavastatin calcium were not elevated(P>0.05). The two groups TC, LDL-C were lower with statistically significant differences(P<0.05). The differences between Glu, ALT, AST, Cr, CK before treatment and after treatment were without statistically differences(P>0.05), 1patient was removed because of transaminase elevated. Conclusion: Both pitavastatin calcium and atorvastatincalcium can lower LDL-C, TC、TG in Coronary Heart Disease patients, Moreover, the pitavastatin calcium can elevate HDL-C level and lower hsCRP level. Meanwhile, the pitavastatin calcium had no evidence in new diabetes, it was efficacy and safety in long-term treatment. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
